i2O Therapeutics, Inc. — Form D
i2O Therapeutics, Inc. of Cambridge, MA, a company, filed a Form D exempt-offering notice with the SEC on 2023-10-18. The offering totals $4.0M, of which $3.5M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2023-10-18
- Form: D
- Accession: 0001782226-23-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $4.0M
- Amount sold: $3.5M
- Remaining: $487K
- Investors: 7
- Date of first sale: 2023-09-18
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-495121
Issuer
- Name: i2O Therapeutics, Inc.
- CIK: 0001782226
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2019
- Address: 610 Main Street, Cambridge, MA, 02139
- Phone: 408-476-1904
Officers, directors & promoters (11)
| Name | Role | Location |
|---|
| Anthony Aiudi | Director | Cambridge, MA |
| Christopher Gagliardi | Director | Cambridge, MA |
| Kurt Graves | Director | Hayward, CA |
| Kurt Graves | Executive Officer | Hayward, CA |
| Katie Ellias | Director | Miami Beach, FL |
| Samir Mitragotri | Director | San Carlos, CA |
| Samir Mitragotri | Executive Officer | San Carlos, CA |
| Ravi Srinivasan | Director | Southlake, TX |
| Ravi Srinivasan | Executive Officer | Southlake, TX |
| Mitragotri Mitragotri | Director | Saratoga, CA |
| Mitragotri Mitragotri | Executive Officer | Saratoga, CA |
Other filings by this issuer (5)
More